Rapport Therapeutics initiated with an Outperform at Citizens JMP

Citizens JMP initiated coverage of Rapport Therapeutics (RAPP) with an Outperform rating and $28 price target Rapport is developing novel precision therapeutics for central nervous system disorders leveraging receptor-associated proteins for targeted and selective function, the analyst tells investors in a research note. The firm believes this approach can produce clinical candidates differentiated from traditional treatments that target receptors distributed throughout the CNS by driving improved safety/tolerability profiles and broader therapeutic indexes.